Mayo Clinic Researcher to Present Findings on Aditxt's ADI-100™ Preclinical Study
Aditxt Inc. will host a May 2 update featuring Mayo Clinic's Dr. Charles Howe discussing key findings from a preclinical study of ADI-100™, offering insights into the company's immune modulation therapy research.
Aditxt Inc. will host a scientific update featuring Dr. Charles Howe from Mayo Clinic, who will present findings from a preclinical study of ADI-100™, the lead therapeutic candidate from Aditxt's subsidiary, Adimune Inc.
The May 2 presentation will include insights from Dr. Shahrokh Shabahang, Aditxt's Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune. The event represents a critical opportunity for stakeholders to understand recent advancements in immune modulation therapy.
Aditxt's innovation platform is focused on accelerating promising health innovations across multiple disciplines. The company currently operates programs in immune health and precision health, with plans to expand into public health and women's health sectors.
The upcoming presentation highlights Aditxt's commitment to collaborative research and its strategy of bringing together research institutions, industry partners, and shareholders to address significant societal health challenges.
Investors and healthcare professionals will be particularly interested in the potential implications of the ADI-100™ preclinical study results, which could provide insights into novel approaches to immune system modulation and treatment.